Delay in imaging versus clinical response: a rationale for prolonged treatment with anti-tumor necrosis factor medication in early rheumatoid arthritis

Arthritis Rheum. 2007 Dec 15;57(8):1564-7. doi: 10.1002/art.23097.
No abstract available

Publication types

  • Clinical Trial
  • Comparative Study

MeSH terms

  • Adult
  • Aged
  • Antibodies, Monoclonal / therapeutic use*
  • Antirheumatic Agents / therapeutic use*
  • Arthritis, Rheumatoid / diagnostic imaging
  • Arthritis, Rheumatoid / drug therapy*
  • Arthritis, Rheumatoid / physiopathology
  • C-Reactive Protein / metabolism
  • Dose-Response Relationship, Drug
  • Drug Therapy, Combination
  • Female
  • Humans
  • Infliximab
  • Joints / diagnostic imaging
  • Joints / physiopathology
  • Male
  • Methotrexate / therapeutic use*
  • Middle Aged
  • Pilot Projects
  • Prospective Studies
  • Quality of Life
  • Remission Induction
  • Synovitis / diagnostic imaging*
  • Time Factors
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*
  • Ultrasonography

Substances

  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • Tumor Necrosis Factor-alpha
  • C-Reactive Protein
  • Infliximab
  • Methotrexate